ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

Dow Jones

29 Jan

By Chris Wack

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene.

The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva.

The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy.

Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population.

ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants.

The primary endpoint of the study is overall survival, with secondary endpoints including disease control rate, progression-free survival, objective response rate and safety.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 29, 2025 10:44 ET (15:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507163016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507163016\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2507163016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507163016","market":"nz","top_or_hot":-1,"title":"ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. \n</p>\n<p>\n  The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva. \n</p>\n<p>\n  The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy. \n</p>\n<p>\n  Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population. \n</p>\n<p>\n  ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants. \n</p>\n<p>\n  The primary endpoint of the study is overall survival, with secondary endpoints including disease control rate, progression-free survival, objective response rate and safety. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2025 10:44 ET (15:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-29 23:44</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. \n</p>\n<p>\n  The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva. \n</p>\n<p>\n  The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy. \n</p>\n<p>\n  Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population. \n</p>\n<p>\n  ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants. \n</p>\n<p>\n  The primary endpoint of the study is overall survival, with secondary endpoints including disease control rate, progression-free survival, objective response rate and safety. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2025 10:44 ET (15:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2507163016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507163016","pubTimestamp":1738165440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene.The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva.The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy.Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population.ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants.The primary endpoint of the study is overall survival, w","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"与百济神州达成合作和供应协议后，ImmunityBio股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1,"IBRX":0.9,"ONC":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. \n\n\n  The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva. \n\n\n  The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy. \n\n\n  Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population. \n\n\n  ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants. \n\n\n  The primary endpoint of the study is overall survival, with secondary endpoints including disease control rate, progression-free survival, objective response rate and safety. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2025 10:44 ET (15:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}